In addition, many genetic alterations affecting tyrosine kinase signaling pathways have recently been identified in various forms of thyroid cancer such as the activating RET mutations present in >95% of hereditary MTC and in 20–50% of sporadic MTC [2, 3]. This evidence concerns the gene RET and medullary thyroid gland carcinoma.